BUZZ-Rein Therapeutics rises as drug for lung‑scarring disease gets EU orphan status
I'm PortAI, I can summarize articles.
Rein Therapeuticsshares rose 2.5% to $1.24 premarket after the company announced that European regulators granted orphan drug status to its experimental therapy, LTI-03, for idiopathic pulmonary fibrosis (IPF). This condition causes severe lung damage. Early preclinical data indicated improved survival and lung function. LTI-03, a synthetic peptide, aims to protect lung cells and inhibit scarring signals. The drug also has U.S. orphan status, and further trials are planned in multiple countries. However, the stock has declined approximately 50% over the past year.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments